By targeting BLM, DENND2D, PHLPP1 or MAOB, miR‐522 could boost tumorigenesis of colorectal cancer, non‐small‐cell lung cancer, glioblastoma and endometrial carcinoma, respectively [20, 25, 26, 29]. Here, MAOB is linked to glioblastoma.